FDA Approves Pozelimab (Veopoz) as First Treatment for CHAPLE Disease
The FDA approval of pozelimab (Veopoz) makes it the first and only treatment indicated for children and adults with CHAPLE disease.
Source: hcplive.com
Stay updated with breaking news from Michael Lenardo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA approval of pozelimab (Veopoz) makes it the first and only treatment indicated for children and adults with CHAPLE disease.
Pozelimab reduced hospitalizations, albumin transfusions in CHAPLE disease patients